Dermatitis News and Research RSS Feed - Dermatitis News and Research

Dermatitis is an infection of the skin. The skin may become itchy and progress to a bumpy red rash that may become tender. There may also be pus-filled blisters that are usually found surrounding hair follicles.
Antiscarring paste can halt fibrosis caused by radiation treatment

Antiscarring paste can halt fibrosis caused by radiation treatment

An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy. That is according to a study led by researchers at Laura and Isaac Perlmutter Cancer Center to be published tomorrow in the January edition of the Journal of the Federation of American Societies for Experimental Biology, or FASEB. [More]
Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune Pharmaceuticals Inc. a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies. [More]
Asthma in childhood may increase risk of shingles

Asthma in childhood may increase risk of shingles

Nearly 1 million incidences of herpes zoster, which is also known as shingles, occur every year in the U.S., with an estimated one-third of all adults affected by age 80. Despite its prevalence, particularly between ages 50 and 59, it is still unclear why some individuals will develop shingles, and others will not. [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
New Northwestern Medicine project aims to understand effects of asthma, eczema on children

New Northwestern Medicine project aims to understand effects of asthma, eczema on children

A new Northwestern Medicine project, "Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments" (AAD-PEPR), will focus on two common childhood diseases that affect almost 25 percent of American children under age 18. [More]
Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC). [More]
First comprehensive genomic and biologic study of top skin disease-causing microbes

First comprehensive genomic and biologic study of top skin disease-causing microbes

An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes. [More]
Allergic response can be unexpected clue in medical mystery

Allergic response can be unexpected clue in medical mystery

Most people think of allergists as the doctors who help solve sneezing, wheezing and itchy eyes. They might not realize allergists are the medical mystery detectives with the expertise to discover what is causing all sorts of unusual allergic responses. [More]
Researchers identify seven genetic risk loci involved in atopic march

Researchers identify seven genetic risk loci involved in atopic march

There's a typical "career" for some allergic people, and it starts very early on the skin: babies develop atopic dermatitis, food allergies may follow, then comes asthma and later on hay fever. A group of scientists led by Ingo Marenholz and Young-Ae Lee at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, working with colleagues from several institutions, has now identified seven genetic risk loci for this course of disease. [More]

BREVENA Laboratories receives National Eczema Association's Seal of Acceptance award for Restorative Skin Balm

BREVENA Laboratories, LLC, a luxury skincare cosmetics company that combines beauty and advanced medical technology, announces that the National Eczema Association has awarded the Seal of Acceptance to the brand's Restorative Skin Balm. [More]
Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP). [More]
OSU researchers develop new approach to treat eczema

OSU researchers develop new approach to treat eczema

Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies. [More]
Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals, Inc. announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
Experts explain how nutrition can influence inflammatory processes and help lower chronic diseases risk

Experts explain how nutrition can influence inflammatory processes and help lower chronic diseases risk

An unresolved inflammatory response is likely to be involved from the early stages of disease development. Controlling inflammation is crucial to human health and a key future preventative and therapeutic target. In a recent ILSI Europe's article published in the British Journal of Nutrition, a coalition of experts explain how nutrition influences inflammatory processes and help reduce chronic diseases risk. [More]
Shorter course of whole breast radiation therapy better for women with early stage breast cancer

Shorter course of whole breast radiation therapy better for women with early stage breast cancer

Women who receive a shorter course of whole breast radiation therapy for early stage disease experience less toxicity and improved quality of life compared to those who undergo a longer course of treatment, researchers report from The University of Texas MD Anderson Cancer Center. [More]

Cipher receives Acceptance Review Notification from FDA for 510(k) submission for Dermadexin

Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration. [More]
Does dandruff cause psychological distress? An interview with Dr Anjali Mahto

Does dandruff cause psychological distress? An interview with Dr Anjali Mahto

Dandruff is a common chronic scalp disorder that is characterised by flaking of the skin of the scalp. As skin cells die, they are shed from the scalp surface. For some people, however, excessive flaking occurs, resulting in dandruff. [More]
Advertisement